0001213900-26-057705
SEC filingQ1 revenue declined amid market volatility and product challenges, yielding gross profit via full equipment depreciation but wider operating losses from intangible amortization, with CEO funding sustaining liquidity.
Revenue of $983.5K declined 13.4% year-over-year, primarily due to lower sales of Omeprazole affected by market volatility, as noted in management's discussion. This pressure reflects broader challenges in maintaining sales momentum amid competitive and regulatory dynamics in the pharmaceutical market.
Gross profit marked a significant turnaround to $285.5K from a prior-year loss of -$136.1K, achieving a 29.0% margin. Management attributes this improvement mainly to certain machinery and equipment reaching the end of their estimated useful lives and becoming fully depreciated, which reduced product costs and enabled the shift from gross loss to profit. This depreciation relief highlights operational efficiencies emerging from prior investments in production assets.
Despite the gross profit gain, operating income deteriorated to -$1.1M, a 47.3% worsening from -$758.6K, driven primarily by higher amortization of intangible assets. Net income followed suit, expanding losses to -$1.1M (45.5% worse year-over-year) with diluted EPS of -$0.04, an improvement from -$0.24 due to share dynamics. These results underscore the drag from non-cash amortization charges on profitability, even as topline gross margins strengthened.
Cash flow from operations used -$55.3K, similar to prior year, with capital expenditures steady at $58.3K, yielding free cash flow of -$113.6K. Management notes principal liquidity sources are operations and bank lines of credit, supplemented by Chairperson and CEO advances for working capital in the period. No assurances exist for continued CEO support, emphasizing reliance on internal cash generation and financing access.
Strategically, the Company plans to focus on cardiovascular and cerebrovascular sectors, optimize its product portfolio, and manage weaker lines to enhance profitability and resilience. As a CMO, it aims to leverage skilled teams, advanced facilities, multiple lines, and quality systems. A new contract promises ongoing production services post-launch for additional revenue and cash inflows. Sufficient capacity for masks supports respiratory protection demand. These initiatives position China Pharma to build on gross margin gains while addressing loss drivers and liquidity needs.